Inflammatory Breast Cancer

Susan Moore

ONF 2005, 32(5), 907-911. DOI: 10.1188/05.ONF.907-911

Case Study

Jump to a section

    References

    Azlina, A.F., Ariza, Z., Arni, T., & Hisham, A.N. (2003). Chronic granulomatous mastitis: Diagnostic and therapeutic considerations. World Journal of Surgery, 27, 515-518.

    Brewer, V.H., Hahn, K.A., Rohrbach, B.W., Bell, J.L., & Baddour, L.M. (2000). Risk factor analysis for breast cellulitis complicating breast conservation therapy. Clinical Infectious Diseases, 31, 654-659.

    Chang, H.R., Slamon, D., Chap, L., Apple, S., Glaspy, J., Lee, P., et al. (2005). Neoadjuvant taxotere (T), carboplatin (C), with or without herceptin (H) for T3 and T4 breast cancer [Abstract 845]. Journal of Clinical Oncology, 23(16, Suppl. 1), 89s.

    Chang, S., Parker, S.L., Pham, T., Buzdar, A.U., & Hursting, S.D. (1998). Inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, 1975-1992. Cancer, 82, 2366-2372.

    Charafe-Jauffret, E., Tarpin, C., Bardou, V.J., Bertucci, F., Ginestier, C., Braud, A.C., et al. (2004). Immunophenotypic analysis of inflammatory breast cancers: Identification of an "inflammatory signature." Journal of Pathology, 202, 265-273.

    Chin, P.L., Anderson, J.S., Somlo, G., Chu, D.Z., Schwarz, R.E., & Ellenhorn, J.D. (2000). Esthetic reconstruction after mastectomy for inflammatory breast cancer: Is it worthwhile? Journal of the American College of Surgeons, 190, 304-309.

    Cristofanilli, M., Buzdar, A.U., & Hortobagyi, G.N. (2003). Update on the management of inflammatory breast cancer. Oncologist, 8, 141-148.

    Galmarini, C.M., Garbovesky, C., Galmarini, D., & Galmarini, F.C. (2002). Clinical outcome and prognosis of patients with inflammatory breast cancer. American Journal of Clinical Oncology, 25, 172-177.

    Giordano, S.H., & Hortobagyi, G.N. (2003). Inflammatory breast cancer: Clinical progress and the main problems that must be addressed. Breast Cancer Research, 5, 284-288.

    Givens, M.L., & Luszczak, M. (2002). Breast disorders: A review for emergency physicians. Journal of Emergency Medicine, 22, 59-65.

    Jaiyesimi, I.A., Buzdar, A.U., & Hortobagyi, G. (1992). Inflammatory breast cancer: A review. Journal of Clinical Oncology, 10, 1014-1024.

    Johnson, P. (2003). Inflammatory breast cancer in primary care. Nurse Practitioner, 28(5), 58-59.

    Kushwaha, A.C., Whitman, G.J., Stelling, C.B., Cristofanilli, M., & Buzdar, A.U. (2000). Primary inflammatory carcinoma of the breast: Retrospective review of mammographic findings. American Journal of Roentgenology, 174, 535-538.

    Lerebours, F., Bieche, I., & Lidereau, R. (2005). Update on inflammatory breast cancer. Breast Cancer Research, 7, 52-58.

    Liao, Z., Strom, E.A., Buzdar, A.U., Singletary, S.E., Hunt, K., Allen, P.K., et al. (2000). Locoregional irradiation for inflammatory breast cancer: Effectiveness of dose escalation in decreasing recurrence. International Journal of Radiation Oncology, Biology, Physics, 47, 1191-1200.

    Montemurro, F., & Aglietta, M. (2005). Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clinical Breast Cancer, 6, 77-80.

    Ozmen, V., Cabioglu, N., Igci, A., Dagoglu, T., Aydiner, A., Kecer, M., et al. (2003). Inflammatory breast cancer: Results of anthracycline-based neoadjuvant chemotherapy. Breast Journal, 9, 79-85.

    Peters, F., Kiesslich, A., & Pahnke, V. (2002). Coincidence of nonpuerperal mastitis and noninflammatory breast cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 105, 59-63.

    Shenkier, T., Weir, L., Levine, M., Olivotto, I., Whelan, T., & Reyno, L. (2004). Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. Canadian Medical Association Journal, 170, 983-994.

    Staren, E.D., Klepac, S., Smith, A.P., Hartsell, W.F., Segretti, J., Witt, T.R., et al. (1996). The dilemma of delayed cellulitis after breast conservation therapy. Archives of Surgery, 131, 651-654.

    Tuma, R.S. (2005). Trastuzumab trials steal show at ASCO meeting. Journal of the National Cancer Institute, 97, 870-871.

    Turpin, E., Bieche, I., Bertheau, P., Plassa, L.F., Lerebours, F., de Roquancourt, A., et al. (2002). Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene, 21, 7593-7597.

    van Golen, K.L. (2003). Inflammatory breast cancer: Relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Research, 5, 174-179.

    van Golen, K.L., Wu, Z.F., Qiao, X.T., Bao, L.W., & Merajver, S.D. (2000). RhoC GTPase, a novel transforming oncogene for human mammory epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Research, 60, 5832-5838.

    Zippel, D., Siegelmann-Danieli, N., Ayalon, S., Kaufman, B., Pfeffer, R., & Zvi Papa, M. (2003). Delayed breast cellulitis following breast conserving operation. European Journal of Surgical Oncology, 29, 327-330.